In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans

Miyuki Omori-Miyake, Masakatsu Yamashita, Yuichiro Tsunemi, Makoto Kawashima, Junji Yagi, Miyuki Omori-Miyake, Masakatsu Yamashita, Yuichiro Tsunemi, Makoto Kawashima, Junji Yagi

Abstract

T helper type 2 (Th2) cytokines, IL-4 and IL-13, attenuate the expression of genes that regulate epidermal cellular structures and the barrier function at the terminal stage of keratinocyte differentiation. However, whether these Th2 cytokines act at earlier stages remains unknown. We investigated the roles of cytokines in expression levels of mRNAs and/or proteins in primary mouse keratinocytes and human keratinocyte HaCaT cells at earlier stages. We showed that IL-4 downregulated the expression levels of Krt1, Krt10, Dsg1, and Dsc1 via IL-4Rα- and signal transducer and activator of transcription factor 6 (STAT6)-dependent mechanisms in differentiating mouse keratinocytes at early stages. As the expression levels of keratin-1 and -10 in the keratinocytes transiently expressing an active form of STAT6 were not downregulated, STAT6 and other IL-4-induced molecules may synergistically regulate this expression. The restoration of the downregulated expression levels of Krt1 and Krt10 induced by IL-4 with the MEK (mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase) inhibitor U0126 indicated the involvement of the p44/42 MAPK signaling pathway in the attenuated expression. IL-13 also downregulated the expression of the four genes. Furthermore, IL-4 or IL-13 caused the downregulation of these genes in HaCaT cells and promoted the fragmentation of cell sheets with mechanical stress. Our results showed that IL-4 or IL-13 acted on differentiating keratinocytes in vitro at early stages to attenuate the gene expression.

References

    1. Nat Rev Immunol. 2010 Apr;10(4):225-35
    1. Exp Dermatol. 2013 Jan;22(1):30-5
    1. Clin Immunol. 2008 Mar;126(3):332-7
    1. J Clin Invest. 2013 Apr;123(4):1556-70
    1. J Investig Dermatol Symp Proc. 2002 Dec;7(1):36-40
    1. J Cell Biol. 2001 Nov 26;155(5):821-32
    1. J Biol Chem. 2011 Jan 14;286(2):1283-91
    1. J Cell Sci. 2012 Apr 1;125(Pt 7):1750-8
    1. Br J Dermatol. 2002 Dec;147(6):1135-41
    1. J Clin Invest. 1994 Aug;94(2):870-6
    1. J Allergy Clin Immunol. 2011 Apr;127(4):954-64.e1-4
    1. Allergy. 2005 Mar;60(3):391-5
    1. J Allergy Clin Immunol. 2007 Jul;120(1):150-5
    1. Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):565-80
    1. J Cell Biol. 1988 Mar;106(3):761-71
    1. J Immunol. 2003 Sep 15;171(6):3262-9
    1. Sci Signal. 2008 Dec 23;1(51):pe55
    1. J Allergy Clin Immunol. 2006 Oct;118(4):930-7
    1. J Allergy Clin Immunol. 2009 Sep;124(3):496-506, 506.e1-6
    1. Trends Immunol. 2010 Nov;31(11):407-13
    1. Immunol Rev. 2008 Dec;226:172-90
    1. Int Immunol. 2004 Aug;16(8):1155-60
    1. Am J Pathol. 2009 Feb;174(2):475-85
    1. J Invest Dermatol. 2001 Oct;117(4):977-83
    1. Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40
    1. Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18507-12
    1. Mol Immunol. 2012 Feb;50(1-2):91-7
    1. Clin Exp Allergy. 2003 Dec;33(12):1717-24
    1. Oncogene. 2001 Oct 11;20(46):6660-8
    1. J Immunol. 2010 Mar 15;184(6):3186-90
    1. FASEB J. 1995 Jun;9(9):726-35
    1. J Cell Sci. 2002 Jul 1;115(Pt 13):2639-50
    1. FEBS Lett. 1999 Dec 24;464(1-2):91-6
    1. J Cell Biol. 2000 Oct 16;151(2):389-400

Source: PubMed

3
订阅